Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

A Blauvelt, RB Warren, K Reich, F Brock, F Fierens, V Ciaravino, M Lebwohl
2020 SKIN The Journal of Cutaneous Medicine  
not available.
doi:10.25251/skin.4.supp.80 fatcat:ducnvjlzmngrzfwnytutmeidle